AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2015-04-27
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55
- Registration Number
- NCT02426541
- Locations
- 🇫🇮
Research Site, Turku, Finland
Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Aclidinium/FormoterolDrug: Placebo
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 267
- Registration Number
- NCT02424344
- Locations
- 🇪🇸
Research Site, Madrid, Spain
A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
Phase 3
Completed
- Conditions
- Diabetes
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 444
- Registration Number
- NCT02419612
- Locations
- 🇬🇧
Research Site, Dundee, United Kingdom
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Biological: Benralizumab
- First Posted Date
- 2015-04-16
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 162
- Registration Number
- NCT02417961
- Locations
- 🇨🇦
Research Site, Quebec, Canada
High Risk Populations Among COPD Patients in Japan
Completed
- Conditions
- COPD
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1016
- Registration Number
- NCT02413359
- Locations
- 🇯🇵
Takenaka Respiratory Clinic, Takarazuka, Hyougo, Japan
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 321
- Registration Number
- NCT02413398
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Coronary Syndrome)
Completed
- Conditions
- Acute Coronary Syndrome
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3000
- Registration Number
- NCT02408224
- Locations
- 🇮🇳
Research Site, Kolkata, West Bengal, India
Brilinta Taiwan Post Approval Safety Study
Phase 4
Completed
- Conditions
- Non ST-elevation Myocardial Infarction
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 108
- Registration Number
- NCT02406248
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Phase 4
Completed
- Conditions
- Cost Sharing, Acute Coronary Syndrome
- Interventions
- Other: Study voucher card
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 11001
- Registration Number
- NCT02406677
- Locations
- 🇵🇷
Research Site, Caguas, Puerto Rico
Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer
Completed
- Conditions
- Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 710
- Registration Number
- NCT02406235
- Locations
- 🇪🇸
Research Site, Zaragoza, SP, Spain